Germline Genetics of Prostate Cancer: Prevalence of Risk Variants and Clinical Implications for Disease Management
Prostate cancer has entered into the era of precision medicine with the recent approvals of targeted therapeutics (olaparib and rucaparib). The presence of germline mutations has important hereditary cancer implications for patients with prostate cancer, and germline testing is increasingly importan...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-04-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/9/2154 |
| _version_ | 1797535783290142720 |
|---|---|
| author | David K. Doan Keith T. Schmidt Cindy H. Chau William D. Figg |
| author_facet | David K. Doan Keith T. Schmidt Cindy H. Chau William D. Figg |
| author_sort | David K. Doan |
| collection | DOAJ |
| description | Prostate cancer has entered into the era of precision medicine with the recent approvals of targeted therapeutics (olaparib and rucaparib). The presence of germline mutations has important hereditary cancer implications for patients with prostate cancer, and germline testing is increasingly important in cancer screening, risk assessment, and the overall treatment and management of the disease. In this review, we discuss germline variants associated with inherited predisposition, prostate cancer risk and outcomes. We review recommendations for germline testing, available testing platforms, genetic counseling as well as discuss the therapeutic implications of germline variants relevant to prostate cancer treatments. Understanding the role of germline (heritable) mutations that affect prostate cancer biology and risk as well as the subsequent effect of these alterations on potential therapies is critical as the treatment paradigm shifts towards precision medicine. Furthermore, enhancing patient education tactics and healthcare system infrastructure is essential for the utilization of relevant predictive biomarkers and the improvement of clinical outcomes of patients with prostate cancer or at high risk of developing the disease. |
| first_indexed | 2024-03-10T11:49:14Z |
| format | Article |
| id | doaj.art-7413b1d581374581bd3f6093640be054 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T11:49:14Z |
| publishDate | 2021-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-7413b1d581374581bd3f6093640be0542023-11-21T17:49:30ZengMDPI AGCancers2072-66942021-04-01139215410.3390/cancers13092154Germline Genetics of Prostate Cancer: Prevalence of Risk Variants and Clinical Implications for Disease ManagementDavid K. Doan0Keith T. Schmidt1Cindy H. Chau2William D. Figg3Emory University Hospital, Atlanta, GA 30322, USAClinical Pharmacology Program, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USAGenitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USAClinical Pharmacology Program, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USAProstate cancer has entered into the era of precision medicine with the recent approvals of targeted therapeutics (olaparib and rucaparib). The presence of germline mutations has important hereditary cancer implications for patients with prostate cancer, and germline testing is increasingly important in cancer screening, risk assessment, and the overall treatment and management of the disease. In this review, we discuss germline variants associated with inherited predisposition, prostate cancer risk and outcomes. We review recommendations for germline testing, available testing platforms, genetic counseling as well as discuss the therapeutic implications of germline variants relevant to prostate cancer treatments. Understanding the role of germline (heritable) mutations that affect prostate cancer biology and risk as well as the subsequent effect of these alterations on potential therapies is critical as the treatment paradigm shifts towards precision medicine. Furthermore, enhancing patient education tactics and healthcare system infrastructure is essential for the utilization of relevant predictive biomarkers and the improvement of clinical outcomes of patients with prostate cancer or at high risk of developing the disease.https://www.mdpi.com/2072-6694/13/9/2154prostate cancergeneticsgermline testing |
| spellingShingle | David K. Doan Keith T. Schmidt Cindy H. Chau William D. Figg Germline Genetics of Prostate Cancer: Prevalence of Risk Variants and Clinical Implications for Disease Management Cancers prostate cancer genetics germline testing |
| title | Germline Genetics of Prostate Cancer: Prevalence of Risk Variants and Clinical Implications for Disease Management |
| title_full | Germline Genetics of Prostate Cancer: Prevalence of Risk Variants and Clinical Implications for Disease Management |
| title_fullStr | Germline Genetics of Prostate Cancer: Prevalence of Risk Variants and Clinical Implications for Disease Management |
| title_full_unstemmed | Germline Genetics of Prostate Cancer: Prevalence of Risk Variants and Clinical Implications for Disease Management |
| title_short | Germline Genetics of Prostate Cancer: Prevalence of Risk Variants and Clinical Implications for Disease Management |
| title_sort | germline genetics of prostate cancer prevalence of risk variants and clinical implications for disease management |
| topic | prostate cancer genetics germline testing |
| url | https://www.mdpi.com/2072-6694/13/9/2154 |
| work_keys_str_mv | AT davidkdoan germlinegeneticsofprostatecancerprevalenceofriskvariantsandclinicalimplicationsfordiseasemanagement AT keithtschmidt germlinegeneticsofprostatecancerprevalenceofriskvariantsandclinicalimplicationsfordiseasemanagement AT cindyhchau germlinegeneticsofprostatecancerprevalenceofriskvariantsandclinicalimplicationsfordiseasemanagement AT williamdfigg germlinegeneticsofprostatecancerprevalenceofriskvariantsandclinicalimplicationsfordiseasemanagement |